SCHEMBL3760358

SCHEMBL3760358

Nc1[c]nc(N)c(-c2ccccc2)c1C(=O)N1CCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.48
MDM2 Q00987 3/20 0.48
HPGD P15428 6/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 3/20 0.45
TSHR P16473 3/20 0.43
RECQL P46063 1/20 0.43
NPC1 O15118 5/20 0.42
GLA P06280 1/20 0.42
RAB9A P51151 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
TLR9 Q9NR96 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 1/20 0.40
CNR1 P21554 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760361 0.90 TP53 (0.48) TP53MDM2HPGDMAPK1KMT2A
SCHEMBL4366295 0.83 TP53 (0.43) TP53MDM2HPGDMAPK1KMT2A
SCHEMBL4366296 0.78 TP53 (0.43) TP53MDM2HPGDMAPK1KMT2A
SCHEMBL3761663 0.77 KMT2A (0.49) TP53MDM2HPGDMAPK1KMT2A
SCHEMBL3759007 0.74 HTT (0.48) TP53MDM2HPGDMAPK1KMT2A
SCHEMBL3765786 0.71 HPGD (0.46) TP53MDM2HPGDMAPK1KMT2A
SCHEMBL3759329 0.70 HPGD (0.44) TP53MDM2HPGDMAPK1KMT2A
SCHEMBL3764989 0.68 SMN1; SMN2 (0.44) TP53MDM2HPGDMAPK1KMT2A
SCHEMBL3752062 0.67 HPGD (0.47) HPGDMAPK1KMT2ATSHRRECQL
SCHEMBL4003333 0.66 LMNA (0.50) HPGDMAPK1KMT2ATSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA TP53 895/4885MDM2 1055/4885HPGD 3366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.